StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Matinas BioPharma's ebitda for the twelve months ending Jun 30, 2026 was -$6.66M. For fiscal 2025 it was -$6.93M. The highest annual figure on record is -$6.93M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.93M–
FY2024Dec 31, 2024-$24.23M–
FY2023Dec 31, 2023-$23.38M–
FY2022Dec 31, 2022-$24.25M–
FY2021Dec 31, 2021-$24.49M–
FY2020Dec 31, 2020-$23.98M–
FY2019Dec 31, 2019-$18.72M–
FY2018Dec 31, 2018-$14.43M–
FY2017Dec 31, 2017-$16.40M–
FY2016Dec 31, 2016-$8.20M–
FY2015Dec 31, 2015-$9.87M–
FY2014Dec 31, 2014-$10.42M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.56M–
Q1 FY2026Mar 31, 2026-$1.94M–
Q4 FY2025Dec 31, 2025-$1.60M–
Q3 FY2025Sep 30, 2025-$1.58M–
Q2 FY2025Jun 30, 2025-$1.83M–
Q1 FY2025Mar 31, 2025-$1.93M–
Q4 FY2024Dec 31, 2024-$8.38M–
Q3 FY2024Sep 30, 2024-$4.29M–
Q2 FY2024Jun 30, 2024-$5.75M–
Q1 FY2024Mar 31, 2024-$5.81M–
Q4 FY2023Dec 31, 2023-$5.79M–
Q3 FY2023Sep 30, 2023-$6.04M–
Q2 FY2023Jun 30, 2023-$6.06M–
Q1 FY2023Mar 31, 2023-$5.49M–
Q4 FY2022Dec 31, 2022-$5.39M–
Q3 FY2022Sep 30, 2022-$5.37M–
Q2 FY2022Jun 30, 2022-$5.84M–
Q1 FY2022Mar 31, 2022-$7.65M–
Q4 FY2021Dec 31, 2021-$6.65M–
Q3 FY2021Sep 30, 2021-$6.82M–
Q2 FY2021Jun 30, 2021-$4.73M–
Q1 FY2021Mar 31, 2021-$6.29M–
Q4 FY2020Dec 31, 2020-$6.43M–
Q3 FY2020Sep 30, 2020-$5.55M–
Q2 FY2020Jun 30, 2020-$5.71M–
Q1 FY2020Mar 31, 2020-$6.29M–
Q4 FY2019Dec 31, 2019-$5.68M–
Q3 FY2019Sep 30, 2019-$4.51M–
Q2 FY2019Jun 30, 2019-$4.47M–
Q1 FY2019Mar 31, 2019-$4.06M–
Q4 FY2018Dec 31, 2018-$4.10M–
Q3 FY2018Sep 30, 2018-$2.90M–
Q2 FY2018Jun 30, 2018-$3.35M–
Q1 FY2018Mar 31, 2018-$4.07M–
Q4 FY2017Dec 31, 2017-$4.59M–
Q3 FY2017Sep 30, 2017-$3.38M–
Q2 FY2017Jun 30, 2017-$3.96M–
Q1 FY2017Mar 31, 2017-$4.48M–
Q4 FY2016Dec 31, 2016-$2.55M–
Q3 FY2016Sep 30, 2016-$1.82M–

More Matinas BioPharma figures

See a number that looks wrong?